Discontinued — last reported Q3 '23
Agilent Technologies Equity Method Investments decreased by 58.6% to $55.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 45.0%, from $100.00M to $55.00M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 5.2% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $111.00M | $130.00M | $120.00M | $125.00M | $128.00M | $136.00M | $141.00M | $126.00M | $121.00M | $124.00M | $102.00M | $102.00M | $108.00M | $112.00M | $101.00M | $100.00M | $61.00M | $59.00M | $133.00M | $55.00M |
| QoQ Change | — | +17.1% | -7.7% | +4.2% | +2.4% | +6.3% | +3.7% | -10.6% | -4.0% | +2.5% | -17.7% | +0.0% | +5.9% | +3.7% | -9.8% | -1.0% | -39.0% | -3.3% | +125.4% | -58.6% |
| YoY Change | — | — | — | — | +15.3% | +4.6% | +17.5% | +0.8% | -5.5% | -8.8% | -27.7% | -19.0% | -10.7% | -9.7% | -1.0% | -2.0% | -43.5% | -47.3% | +31.7% | -45.0% |